Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962896 | 1.00 | ALDH1A1 (0.63) | ALDH1A1CCR1KMT2AMEN1HSD11B1 | |
| SCHEMBL4962889 | 1.00 | ALDH1A1 (0.63) | ALDH1A1CCR1KMT2AMEN1HSD11B1 | |
| SCHEMBL4966359 | 0.94 | ALDH1A1 (0.67) | ALDH1A1CCR1HSD11B1 | |
| SCHEMBL4966350 | 0.94 | ALDH1A1 (0.67) | ALDH1A1CCR1HSD11B1 | |
| SCHEMBL4003532 | 0.90 | ALDH1A1 (0.64) | ALDH1A1CCR1HSD11B1 | |
| SCHEMBL4003536 | 0.90 | ALDH1A1 (0.64) | ALDH1A1CCR1HSD11B1 | |
| SCHEMBL4964636 | 0.86 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL4965681 | 0.86 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL4967394 | 0.86 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL4965245 | 0.79 | DRD2 (0.63) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| EP-1773780-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1773780-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012227-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | ALDH1A1 345/4885CCR1 2867/4885KMT2A 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.